Vol.57 No.2 March 2009

Pharmacokinetics of clarithromycin dry syrup in pediatric respiratory tract infection

Hideaki Sakata¹⁾, Nodoka Adachi²⁾, Kinji Tatsuno³⁾ and Keisuke Sunakawa⁴⁾

¹⁾Faculty of Health Sciences, Mejiro University, 320 Ukiya, Iwatsuki-ku, Saitama, Japan
²⁾Department of Otolaryngology, Saitama Children's Medical Center
³⁾GCP Audit Section, Taisho Pharmaceutical Co., Ltd.
⁴⁾Kitasato University Graduate School of Infection Control Sciences

Abstract

We report the pharmacokinetic parameters of Clarith^®dry syrup 10% for pediatric in upper respiratory tract infection.
Six subjects - 5 boys and 1 girl - age 6-10 (7.3±1.6) years and having upper respiratory tract infection were treated with a 5 mg (potency)/kg oral dose of clarithromycin (CAM). Each had 6 blood samples taken with a 6-hour period after CAM administration.
Based on high-performance liquid chromatography combined with an electrochemical detector (ECD-HPLC), we quantitatively analyzed CAM and (14R)-14-hydroxy-CAM (M-5) in serum.
The ratio against pharmacokinetic parameters was as follows:
For CAM, C_max 1.05±0.33 μg/mL, AUC 3.54±1.14 μg·h/mL, and T_1/2 1.78±0.28 h.
For M-5, C_max 0.98±0.27 μg/mL, AUC 5.37±1.68 μg·h/mL, and T_1/2 3.17±0.59 h.

Key word

clarithromycin, dry syrup, pharmacokinetics, child

Received

June 23, 2008

Accepted

December 19, 2008

Jpn. J. Chemother. 57 (2): 97-100, 2009